Second pivotal, randomized, blinded placebo-controlled trial of Naronapride for treatment of GI motility disorders.

Trial Profile

Second pivotal, randomized, blinded placebo-controlled trial of Naronapride for treatment of GI motility disorders.

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Naronapride (Primary)
  • Indications Gastrointestinal motility disorders
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 01 Dec 2016 New trial record
    • 16 Nov 2016 According to a Renexxion media release, company has received positive guidance on the design of this trial, required for NDA filing for naronapride by U. S. FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top